MFJ International, LLC A Global Consulting Firm “FTAs and Pharmaceuticals: a hijacked process?” M. Fabiana Jorge CPTECH November 16, 2006.

Slides:



Advertisements
Similar presentations
Caribbean Central American Action (CCAA) Strengthening in the Third Border (CBI) CCA 27 th Annual Miami Conference on the Caribbean Basin Dr Rosanna Cooper,
Advertisements

Impact of JUSFTA on affordability and availability of medicines from perspective of local generic manufacturers Towards equitable and affordable medicine.
Ind – Develop a foundational knowledge of pricing to understand its role in marketing. (Part II) Entrepreneurship I.
1 WTO and medicines: from Doha to Cancún Germán Velásquez Essential Drugs and Medicines Policy World Health Organization Geneva, October 2003.
2 nd WIPO Inter-Regional Meeting on South- South Cooperation on Patents, Trademarks, Geographical Indications, Industrial Designs and Enforcement Cairo.
What You Need to Know About Biosimilars: Products, Recent Deals, IP Issues and Licensing August 2, 2012 Madison C. Jellins 1.
Using FTA Side Letters and Congressional Letters to Authorize Waiver of Data Exclusivity and Linkage Professor Brook K. Baker Northeastern U. School of.
1 New Delhi 12 May 2011 by D G Shah Secretary General Indian Pharmaceutical Alliance Pharmaceutical Innovation Issues & Challenges RIS and Indian Council.
Software patents, innovation and competition policy Rishab Aiyer Ghosh & Luc Soete MERIT, Universiteit Maastricht.
1 Review of Art 39.3 TRIPS – interpretation and controversy Sanya Smith Third World Network 25 August 2006 Bangkok.
Patent linkage and the TPP Commercial considerations relevant to TPP 1 Geraldine Storton Hospira Pty Ltd.
National symposium on Competition law: Evolution and Transition, 2012 Competition Policy for IP Issues Pradeep S Mehta Secretary General, CUTS International.
Possible Impact of Market Exclusivity Extension on Pharmaceuticals in Thailand Chutima Akaleephan International Health Policy Program, Thailand 27 August.
“Using Competition Law to Promote Access to Health Technologies” Access to Innovation: Making Generic Versions of Newer ARVs Affordable 24 July 2014 Melbourne,
Health Professional Students AIDS Advocacy Network Treat the People: Access to Essential AIDS Medications A Primer for Health Professional Students.
Patent Law Issues in Recent FTAs Joshua D. Sarnoff Washington College of Law American University Washington, DC, USA IP, FTAs,
Global Versus Localized Marketing Global marketing emphasizes selling the same product with the same marketing mix all over the world Localized marketing.
MFJ International, LLC A Global Consulting Firm IP and FTAs: Significant Issues in Current Negotiations and their Relation to US IP Laws Workshop on IP,
Developed by Cool Pictures and MultiMedia Presentations Copyright © 2004 by South-Western, a division of Thomson Learning, Inc. All rights reserved. Developed.
Intellectual Property, Free Trade Agreements and sustainable Development Hanan Sboul Secretary General/ The Jordanian Association of Pharmaceutical Manufacturers.
Industry Trends and Tools for Generic Product Selection KATE KUHRT SHANGHAI JUNE 19-21, 2007.
IP News 指導老師:李柏靜 學生:黃馨葦 M /3/26.  Citing the high cost of one of the pharmaceutical industry's expensive new cancer drugs, India's patent.
Critical Success Factors for the Korean Generic and API Industry in a post FTA Environment DAVID HARDING SEOUL JUNE 28-29, 2007.
Drug Pricing in Canada Victoria Brown, Anureet Sohi, Lisa Weger SPHA 511.
International Max Planck Research School for Competition and Innovation WIPO – Owais Hassan Shaikh IMPRS-CI 2010 Data Exclusivity in Free Trade.
The TRIPs Amendment: Developments and implications Tralac/ Comomonwealth post Hong Kong Conference 10 April 2006 Tenu Avafia UNDP.
Copyright © 2011 by The McGraw-Hill Companies, Inc. All rights reserved. McGraw-Hill/Irwin Global Business Today 7e by Charles W.L. Hill.
A very short introduction to patents & access to medicines.
Chapter 5 Global Management. Learning Outcomes 1.Define global management 2.Compare and contrast importing and exporting 3.Explain the advantages and.
TRIPS, Doha and Access to Medicines: Recent Lessons CARSTEN FINK Globalization, Intellectual Property Rights and Social Equity: Challenges and Opportunities.
PATENTS AND HEALTH. A CASE STUDY OF THE UGANDAN CONTEXT. (PHA3 JULY 7 TH 2012 –CAPE TOWN, SOUTH AFRICA) MS. MARIAM AKIROR LLB (HONS) / DIP. SW / CPC. PROG.
Restrictions on exports of medicine: irrational public policy, backdoor efforts to marginalize compulsory licensing, or Northern protectionism? James Love.
International Max Planck Research School for Competition and Innovation WIPO – Owais Hassan Shaikh IMPRS-CI 2010 Data Exclusivity Provisions.
D OHA N EGOTIATIONS & I NDIA P resenters * E vgeniya Burova * M ohini Patel.
Multinational business
TRIPS plus FTAs Rohit Malpani Oxfam America. Public health consequences of TRIPS plus FTAs Prospective studies on FTAs with TRIPS plus provisions –US.
WHO Perspective on Medicine Patents and FTAs Asian Regional Workshop on FTAs August, 2005, Kuala Lumpur, Malaysia Dr Zafar Mirza Regional Adviser,
UNCTAD/CD-TFT 1 Intellectual Property Rights and National Development Goals – Ensuring Innovation in Russia St. Petersburg/Moscow Study Tour 2008 Christoph.
Ideas in Development The Potential Impact of WTO Accession, FTAs and Partnership & Cooperation Agreements (PCAs) on Access to Medicines.
UNCTAD/CD-TFT 1 Exclusive Rights and Public Access – Flexibilities in International Agreements and Development Objectives The Public Health Example 21.
UNCTAD/CD-TFT 1 IP Provisions in Bilateral & Regional Trade Agreements and Public Health ICTSD/QUNO Dinner Discussion on IPRs in Bilateral & Regional Trade.
© 2014 by McGraw-Hill Education. This is proprietary material solely for authorized instructor use. Not authorized for sale or distribution in any manner.
Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“
National Seminar on Intellectual Property and its Impact on Economic Development The Role of Intellectual Property in Promoting International Trade and.
Presentation to Civil Society meeting Harare 21 January 2014.
Managing Procurement and Logistics of HIV/AIDS Drugs and Related Supplies By Yvonne Nkrumah Legal Counsel, Ghana Food and Drugs Board.
‘Linkage’ & other TRIPS+ provisions: a public health perspective Karin Timmermans World Health Organization Seminar “Data exclusivity and patent Bangkok.
Ellen ‘t Hoen Médecins sans Frontières
PRIORITIZING HEALTH IN U.S. TRADE POLICY: A CASE EXAMPLE.
Protection of Intellectual Property in Canada George Jackowski, Ph.D., KCTJ October 19 th, 2015 Chairman of NAVA Corp.
Industry’s Perspective on Industry-University Intellectual Property External Research Directors Network Industrial Research Institute, Inc. April 17, 2001.
Uniting Forces for Access to Hepatitis C Treatment Global Epidemiology Global Epidemiology & Treatment Access Issues & Treatment Access Issues Tracy Swan.
The Role of New Markets Advisors in Healthcare Case Study in Pharma.
The Intellectual Property Provisions of Recent US FTAs CARSTEN FINK Video Conference for Andean Countries on Intellectual Property Rights, May 4, 2005.
TRIPS-Plus Pressures: Trade Agreements, and New Trade Policy Prof. Brook K. Baker OSI Kiev – IPRs & A2M, Sept. 16, 2009.
Level 1 Business Studies AS90838 Demonstrate an understanding of external factors influencing a small business BS 12/2/2.
Intellectual Property Negotiations Between the United States and Colombia, Peru and Equator for a Free Trade Agreement, Relating to Medicine James Love.
Recent FTC Pharmaceutical Cases: Background and Examples Sue H. Kim This presentation was prepared from public sources. The views expressed herein do not.
NAFTA, CAFTA and Access to Medicines and Food Security in Latin America International Aids Conference Session “Globalization and FTAs: their impact, access.
iHEA 9th World Congress Sydney, July 8, 2013
Dialogue on Competition Policy and Intellectual Property *
Intellectual Property, Free Trade Agreements and sustainable Development Hanan Sboul Secretary General/ The Jordanian Association of Pharmaceutical Manufacturers.
Free Trade and Intellectual Property Rights: Implications for the Canadian Pharmaceutical Environment Joel Lexchin MD School of Health Policy & Management.
Intellectual Property Protection and Access to Medicines
PATENTS, TRIPS, FLEXIBILITIES & ACCESS TO MEDICINES
An Increasing Demand for Prescription Drugs Drives Profitability
Report Code :CM 1335 India Pharmaceuticals Market Outlook 2025: Opportunity & Growth Analysis,
Report Code :CM 1335 India Pharmaceuticals Market Outlook 2025: Opportunity & Growth Analysis,
Pharmaceuticals Industry
Dr. Achim Seiler, EU-Project” Support of Yemen’s Accession to the WTO”
Presentation transcript:

MFJ International, LLC A Global Consulting Firm “FTAs and Pharmaceuticals: a hijacked process?” M. Fabiana Jorge CPTECH November 16, 2006

MFJ International, LLC A Global Consulting Firm AGENDA Global Pharmaceutical Market before and after TRIPS Negotiating for the future: The cutting edge provisions of the FTAs. The need to change

MFJ International, LLC A Global Consulting Firm I. Global Pharmaceutical Market before and after TRIPS Worldwide Pharmaceutical -- Sales 1994 Total Sales: $246.4 billion Source: IMS

MFJ International, LLC A Global Consulting Firm Total Sales: $565.9bn Source: IMS I.Global Pharmaceutical Market before and after TRIPS Worldwide Pharmaceutical -- Sales 2005

MFJ International, LLC A Global Consulting Firm I. Global Pharmaceutical Market before and after TRIPS Total global pharmaceutical sales $246.4B565.9 (100%)(230%)

MFJ International, LLC A Global Consulting Firm I. Global Pharmaceutical Market before and after TRIPS Distribution of global pharmaceutical sales US, Europe, Japan 1994:82% US, Europe, Japan 2005:88%

MFJ International, LLC A Global Consulting Firm I. Global Pharmaceutical Market before and after TRIPS "The pharmaceutical industry today sells 80 per cent of its products to 20 per cent of the world's population..." Jean-Pierre Garnier Financial Times (London, England) July 22, 2005 Friday

MFJ International, LLC A Global Consulting Firm I. Global Pharmaceutical Market before and after TRIPS Now, if brand name companies want to keep increasing their revenue maximization, what would their strategy be? To sell more and more expensive drugs where people can pay for them or to try to sell more in markets where people have less resources?

MFJ International, LLC A Global Consulting Firm I. Global Pharmaceutical Market before and after TRIPS USTR strategy in FTAs: –Increase level of IPR protection forcing smaller partners to adopt such standards –Create enough critical mass and later harmonize standards of protection –Success of strategy: when the big markets adopt such new levels of IP protection

MFJ International, LLC A Global Consulting Firm II. Negotiating for the future: the cutting edge provisions of the FTAs. Profit maximization through: –In developing countries: elimination of the use of flexibilities such as compulsory licensing, parallel imports, restrictions to patentable subject matter. –In developed countries: blocking generic competition through patent extensions, linkage provisions and market exclusivity.

MFJ International, LLC A Global Consulting Firm II. Negotiating for the future: the cutting edge provisions of the FTAs. Patent Extensions: They do not include the limits that exist under US law (5y; 14y EPT) Eventually it could lead to their elimination in the US; Potential effect? We have the lessons from TRIPS: Prof Schondelmeyer’s study

MFJ International, LLC A Global Consulting Firm II. Negotiating for the future: the cutting edge provisions of the FTAs. Market Exclusivity –At least –NCE vs. new pharmaceutical product –Same or similar –Can go beyond patent term –Required or permitted –Dropping the word “undisclosed”

MFJ International, LLC A Global Consulting Firm II. Negotiating for the future: the cutting edge provisions of the FTAs. Elimination of Best Mode requirement Focus: biotechnology industry and litigation cases

MFJ International, LLC A Global Consulting Firm II. Negotiating for the future: the cutting edge provisions of the FTAs. Linkage FTAs do not include limits or requirements that exist in US law NCE Lawsuits Can be challenged Objective: to block all patents and eventually eliminate Bolar

MFJ International, LLC A Global Consulting Firm III. Conclusions FTAs process has been “hijacked” by brand name pharmaceutical companies The process in the US to define the trade policy on pharmaceuticals is far from being democratic This trade policy hurts US generic companies Brand name pharmaceuticals will continue using FTAs as tools to increase their monopolies and obtain profit maximization New Congress: great opportunity to try to reach a better balance

MFJ International, LLC A Global Consulting Firm III. Conclusions Congress should at the very least approve an amendment that should apply to all past FTAs as well to ensure that all limits in US law should be respected (i.e. limits on patent extensions). Need for specific language Ultimately: other countries need to stop these negotiations or negotiate better

MFJ International, LLC A Global Consulting Firm Thank you!